Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹M.D. Asistant Professor, Pamukkale University Faculty of Medicine, Department of Ophthalmology, Denizli/TURKEY
²M.D. Associate Professor, Saint Louis University Faculty of Medicine, Department of Ophthalmology, Saint Louis/USA Up to date there is no golden standard for the treatment of non-arteritic ischemic optic neuropathy. Here we report two cases which underwent intravitreal bevacizumab injection for non-arteritic ischemic optic neuropathy. In the first case, visual acuity changed from 2/200 to 20/400 at 2 week and 4/200 at one year. In the second case, visual acuity decreased from 20/30 to 20/400 with a worsened visual field defect at 6 week and to 20/200 at 5.5 month. Bevacizumab did not seem to improve visual outcome in non-arteritic ischemic optic neuropathy. Keywords : Anti-vascular endothelial growth factor, bevacizumab, non-arteritic ischemic optic neuropathy